Cart (Loading....) | Create Account
Close category search window

Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

11 Author(s)

This paper describes preliminary results in a murine model devoted to monitoring breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound (US). Twenty mice were implanted with 2LMP breast cancer cells. Three weeks thereafter, 10 mice were administered a 0.1 mg i.p. injection of bevacizumab whereas the remaining mice received saline injections. Using a Philips iU22 scanner equipped with an L9-3 transducer, baseline and follow-up imaging at day 6 was performed using contrast-enhanced US and flash-replenishment techniques. Contrast agent flow (i.e., time-intensity curves) and tumor reperfusion parameters were derived from US image sequences and a given region-of-interest (ROI). Experimental results showed reperfusion metrics were greater for tumors treated with bevacizumab compared to controls. Significant differences found in the AUC (p < 0.01) and Ipk (p < 0.01) time-intensity curve parameters maybe due to a reduction in intratumoral pressures and restored tumor flow. No significant differences were found between control and treated tumors for either the Tpk parameter (p = 0.20) or tumor size (p = 0.18). Histological results revealed increased microvessel density (MVD) for control tumors (p < 0.01) when compared to treated mice. No significant differences in tumor necrosis levels (p = 0.18) were found between control and therapy tumor groups. Overall, these preliminary experiments demonstrate that changes in tumor vascularity and perfusion kinetics in response to antiangiogenic therapy can be distinguished using contrast-enhanced US techniques.

Published in:

Ultrasonics Symposium (IUS), 2009 IEEE International

Date of Conference:

20-23 Sept. 2009

Need Help?

IEEE Advancing Technology for Humanity About IEEE Xplore | Contact | Help | Terms of Use | Nondiscrimination Policy | Site Map | Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest professional association for the advancement of technology.
© Copyright 2014 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.